-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OtYUh4S2zze5ngtw0Nu61WrpS5obw6jgD6/HcND/C6z/xLpXFeOpkE6i6CuvMtQV qdyF/EtOZzsNsAj50eBo5Q== 0000898432-08-001261.txt : 20081210 0000898432-08-001261.hdr.sgml : 20081210 20081210161242 ACCESSION NUMBER: 0000898432-08-001261 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20081210 DATE AS OF CHANGE: 20081210 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF INVESTMENTS, L.L.C. GROUP MEMBERS: BVF PARTNERS L.P. GROUP MEMBERS: INVESTMENT 10, L.L.C. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: COMBINATORX, INC CENTRAL INDEX KEY: 0001135906 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043514457 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81444 FILM NUMBER: 081241244 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: 16TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-301-7000 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: 16TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: COMBINATORX INC DATE OF NAME CHANGE: 20010301 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 SC 13D/A 1 sc13da.htm

OMB APPROVAL

OMB Number: 3235-0145

Expires: February 28, 2009

Estimated average burden
hours per response. . . 14.5



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

Combinatorx, Incorporated

(Name of Issuer)

Common Stock

(Title of Class of Securities)

20010A103

(CUSIP Number)

Elizabeth Delaney
BVF Partners L.P.
900 North Michigan Avenue
Suite 1100
Chicago, Illinois 60611

(312) 506-6500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 5, 2008

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [X]

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

1.

Names of Reporting Persons.
Biotechnology Value Fund, L.P.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     [X]
(b)     
[ ]

3.

SEC Use Only

4.

Source of Funds (See Instructions) WC

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

[ ]

6.

Citizenship or Place of Organization
Delaware

Number of Shares Beneficially Owned by Each Reporting Person With

7.

Sole Voting Power

0

8.

Shared Voting Power

2,391,971

9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

2,391,971

11.

Aggregate Amount Beneficially Owned by Each Reporting Person   2,391,971

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  [ ]

13.

Percent of Class Represented by Amount in Row (11):   6.82%

14.

Type of Reporting Person (See Instructions):   PN

 


1.

Names of Reporting Persons.
Biotechnology Value Fund II, L.P.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     [X]
(b)     
[ ]

3.

SEC Use Only

4.

Source of Funds (See Instructions)   WC

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

[ ]

6.

Citizenship or Place of Organization
Delaware

Number of Shares Beneficially Owned by Each Reporting Person With

7.

Sole Voting Power

0

 

8.

Shared Voting Power

1,665,900

 

9.

Sole Dispositive Power

0

 

10.

Shared Dispositive Power

1,665,900

11.

Aggregate Amount Beneficially Owned by Each Reporting Person:   1,665,900

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  [ ]

13.

Percent of Class Represented by Amount in Row (11):   4.75%

14.

Type of Reporting Person (See Instructions):   PN

 

 

1.

Names of Reporting Persons.
BVF Investments, L.L.C.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     [X]
(b)     
[ ]

3.

SEC Use Only

4.

Source of Funds (See Instructions)   WC

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

[ ]

6.

Citizenship or Place of Organization
Delaware

Number of Shares Beneficially Owned by Each Reporting Person With

7.

Sole Voting Power

0

8.

Shared Voting Power

5,951,000

9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

5,951,000

11.

Aggregate Amount Beneficially Owned by Each Reporting Person:   5,951,000

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  [ ]

13.

Percent of Class Represented by Amount in Row (11):   16.96%

14.

Type of Reporting Person (See Instructions):   OO

 


 

1.

Names of Reporting Persons.
Investment 10, L.L.C.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     [X]
(b)     
[ ]

3.

SEC Use Only

4.

Source of Funds (See Instructions)   WC

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

[ ]

6.

Citizenship or Place of Organization
Illinois

Number of Shares Beneficially Owned by Each Reporting Person With

7.

Sole Voting Power

0

8.

Shared Voting Power

640,400

9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

640,400

11.

Aggregate Amount Beneficially Owned by Each Reporting Person:   640,400

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  [ ]

13.

Percent of Class Represented by Amount in Row (11):   1.82%

14.

Type of Reporting Person (See Instructions):   OO

 

 

1.

Names of Reporting Persons.
BVF Partners L.P.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     [X]
(b)     
[ ]

3.

SEC Use Only

4.

Source of Funds (See Instructions)   OO

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

[ ]

6.

Citizenship or Place of Organization
Delaware

Number of Shares Beneficially by Owned by Each Reporting Person With

7.

Sole Voting Power

0

 

8.

Shared Voting Power

10,649,271

 

9.

Sole Dispositive Power

0

 

10.

Shared Dispositive Power

10,649,271

11.

Aggregate Amount Beneficially Owned by Each Reporting Person:   10,649,271

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  [ ]

13.

Percent of Class Represented by Amount in Row (11):   30.35%

14.

Type of Reporting Person (See Instructions):   PN, HC

 

 

1.

Names of Reporting Persons.
BVF Inc.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     [X]
(b)     
[ ]

3.

SEC Use Only

4.

Source of Funds (See Instructions) OO

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

[ ]

6.

Citizenship or Place of Organization
Delaware

Number of Shares Beneficially by Owned by Each Reporting Person With

7.

Sole Voting Power

0

 

8.

Shared Voting Power

10,649,271

 

9.

Sole Dispositive Power

0

 

10.

Shared Dispositive Power

10,649,271

11.

Aggregate Amount Beneficially Owned by Each Reporting Person: 10,649,271

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  [ ]

13.

Percent of Class Represented by Amount in Row (11):   30.35%

14.

Type of Reporting Person (See Instructions):   CO, HC

 

 

ITEM 1. Security and Issuer

This Schedule 13D/A relates to the common stock, par value $0.001 per share (the “Common Stock”) of Combinatorx, Incorporated, a Delaware corporation (“CRXX”). The principal executive office of CRXX is located at 245 First Street, Sixteenth Floor, Cambridge, MA 02142.

ITEM 3. Source and Amount of Funds or Other Consideration
Partners, in its capacity as (i) general partner of BVF, has purchased on behalf of such limited partnership an aggregate number of 2,391,971 shares of the Common Stock for an aggregate consideration of $4,908,473, (ii) general partner of BVF2, has purchased on behalf of such limited partnership an aggregate number of 1,665,900 shares of Common Stock for an aggregate consideration of $3,457,894, (iii) manager of BVLLC, has purchased on behalf of such limited liability company an aggregate number of 5,951,000 shares of Common Stock for an aggregate consideration of $12,066,108, and (iv) investment adviser to ILL10, purchased on behalf of such limited liability company an aggregate of 640,400 shares of Common Stock for an aggregate consideration of $1,388,264. Each of BVF, BVF2, BVLLC and ILL10 purchased the shares held by it using its own working capital. No borrowed funds were used to purchase the Common Stock other than any borrowed funds used for working capital purposes in the ordinary course of business.

ITEM 5. Interest in Securities of the Issuer

The Reporting Persons’ percentage ownership of Common Stock is based on 35,093,587 shares being outstanding.
 
(a)     As of December 5, 2008, BVF beneficially owns 2,391,971 shares of Common Stock, BVF2 beneficially owns 1,665,900 shares of Common Stock, BVLLC beneficially owns 5,951,000 shares of Common Stock, ILL10 beneficially owns 640,400 shares of Common Stock and each of Partners and BVF Inc. may be deemed to beneficially own 10,649,271 shares of Common Stock, representing percentage ownership of approximately 6.82%, 4.75%, 16.96%, 1.82% and 30.35%, respectively.

(b)     Each of BVF, BVF2, BVLLC and ILL10 shares with Partners voting and dispositive power over the Common Stock each such entity beneficially owns. Partners and BVF Inc. share voting and dispositive power over the 10,649,271 shares of Common Stock they may be deemed beneficially to own with BVF, BVF2 and BVLLC, and ILL10.

(c)     Purchases of Common Stock within the last 60 days have been made by the following Reporting Persons:

     

BVF

ILL10

BVF2

BVLLC

 

Date of Transaction

Type of Securities

Price Per Share

       

EXCHANGE

10/06/08

Common Stock

0.7599

227,000

58,000

158,000

574,000

NASDAQ

10/07/08

Common Stock

0.6557

188,000

47,000

130,000

472,000

NASDAQ

10/08/08

Common Stock

0.6191

24,100

6,000

17,000

62,000

NASDAQ

10/10/08

Common Stock

0.5985

13,300

3,000

10,000

35,000

NASDAQ

10/13/08

Common Stock

0.6490

6,500

1,000

4,000

15,000

NASDAQ

10/15/08

Common Stock

0.6500

169,000

43,000

117,000

426,000

NASDAQ

10/16/08

Common Stock

0.6500

482,000

122,000

334,000

1,215,000

NASDAQ

11/05/08

Common Stock

0.5997

42,400

11,000

30,000

108,000

NASDAQ

11/06/08

Common Stock

0.5879

2,200

1,000

2,000

7,000

NASDAQ

11/07/08

Common Stock

0.5767

26,700

7,000

18,000

65,000

NASDAQ

11/10/08

Common Stock

0.5800

4,000

1,000

2,000

8,000

NASDAQ

11/11/08

Common Stock

0.5983

33,100

8,000

23,000

83,000

NASDAQ

11/12/08

Common Stock

0.5998

600

-

1,000

2,000

NASDAQ

11/13/08

Common Stock

0.6000

1,000

1,000

2,000

6,000

NASDAQ

11/14/08

Common Stock

0.5963

1,200

1,000

2,000

6,000

NASDAQ

11/21/08

Common Stock

0.4500

3,000

1,000

2,000

7,000

NASDAQ

11/24/08

Common Stock

0.4500

20,100

5,000

14,000

49,000

NASDAQ

11/25/08

Common Stock

0.4678

3,300

1,000

2,000

7,000

NASDAQ

11/25/08

Common Stock

0.4600

-

2,400

-

-

NASDAQ

11/26/08

Common Stock

0.4940

1,600

-

1,000

4,000

NASDAQ

12/01/08

Common Stock

0.5500

6,800

2,000

4,000

16,000

NASDAQ

12/02/08

Common Stock

0.5465

1,800

1,000

2,000

6,000

NASDAQ

12/03/08

Common Stock

0.5385

3,400

1,000

2,000

8,000

NASDAQ

12/04/08

Common Stock

0.5500

2,300

1,000

2,000

6,000

NASDAQ

12/05/08

Common Stock

0.5700

354,872

91,000

245,000

878,000

NASDAQ

12/05/08

Common Stock

0.5698

1,700

-

1,000

3,000

NASDAQ

12/05/08

Common Stock

0.5700

11,000

3,000

8,000

28,000

NASDAQ



_______________________________________________________________________________________________________________

ITEM 7. Material to be filed as Exhibits

A Joint Filing Agreement on behalf of the Reporting Persons is filed herewith as Exhibit A.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: December 10, 2008
 

 

BIOTECHNOLOGY VALUE FUND, L.P.*

   
 

By: BVF Partners L.P., its general partner

   
 

By:

BVF Inc., it’s general partner

   
 

            By:   /s/ Mark N. Lampert

                    Mark N. Lampert
                       President


 

BIOTECHNOLOGY VALUE FUND II, L.P.*

   
 

By: BVF Partners L.P., its general partner

   
 

By:

BVF Inc., it’s general partner

   
 

              By:  /s/ Mark N. Lampert

                      Mark N. Lampert
                      President

 
 

 

BVF INVESTMENTS, L.L.C.*

   
 

By: BVF Partners L.P., its manager

   
 

By:

BVF Inc., it’s general partner

   
 

                    By:   /s/ Mark N. Lampert

   

         Mark N. Lampert
         President



 

INVESTMENT 10, L.L.C.*

   
 

By: BVF Partners L.P., its investment manager

   
 

By:

BVF Inc., it’s general partner

   
 

                    By:   /s/ Mark N. Lampert

   

         Mark N. Lampert
         President



 

BVF PARTNERS, L.P.*

   
 

By:

BVF Inc., it’s general partner

 

                    By:   /s/ Mark N. Lampert

   

         Mark N. Lampert
         President



 

BVF INC.*

 
 

By:   /s/ Mark N. Lampert

         Mark N. Lampert
          President

*The Reporting Person disclaims beneficial ownership except to the extent of its pecuniary interest therein.

Exhibit A

JOINT FILING AGREEMENT

The undersigned agree that this Schedule 13D/A dated December 10, 2008, relating to the Common Stock of CRXX shall be filed on behalf of the undersigned.

 

BIOTECHNOLOGY VALUE FUND, L.P.*

   
 

By: BVF Partners L.P., its general partner

   
 

By:

BVF Inc., it’s general partner

   
 

                    By:   /s/ Mark N. Lampert

   

         Mark N. Lampert
         President



 

BIOTECHNOLOGY VALUE FUND II, L.P.*

   
 

By: BVF Partners L.P., its general partner

   
 

By:

BVF Inc., it’s general partner

   
 

                    By:  /s/ Mark N. Lampert

   

         Mark N. Lampert
         President



 

BVF INVESTMENTS, L.L.C.*

   
 

By:   BVF Partners L.P., its manager

   
 

         By:   BVF Inc., it’s general partner

   
 

                  By:  /s/ Mark N. Lampert

   

       Mark N. Lampert
       President



 

INVESTMENT 10, L.L.C.*

   
 

By:   BVF Partners L.P., its investment manager

   
 

         By:  BVF Inc., it’s general partner

   
 

                By:  /s/ Mark N. Lampert

   

     Mark N. Lampert
     President



 

BVF PARTNERS, L.P.*

 

By:

BVF Inc., it’s general partner

   
 

                           By:  /s/ Mark N. Lampert

   

         Mark N. Lampert
         President


 

BVF INC.*

   
 

By:   /s/ Mark N. Lampert

         Mark N. Lampert
         President


-----END PRIVACY-ENHANCED MESSAGE-----